SANDPIPER THERAPEUTICS
Live / Allowed — Notice of allowance issued (as of 21 Oct 2025)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 07 Jan 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 98942955
- Mark type
- Stylized text
- Filed
- 07 Jan 2025
- Published for opposition
- 26 Aug 2025
- Attorney of record
- Aaron D. Hendelman
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for use in oncology, immunology, cardiometabolic diseases, and cardiovascular diseases; biological preparations for use in cell culture for medical purposes related to oncology, immunology, cardiometabolic diseases, and cardiovascular diseases; therapeutic pharmaceuticals for use in oncology, immunology, cardiometabolic diseases, and cardiovascular diseases; biological therapies in the nature of pharmaceutical preparations for use in oncology, immunology, cardiometabolic diseases, and cardiovascular diseases
- Class 042 — Scientific and technological services: research and development in the field of small molecule drug discovery for use in oncology, immunology, cardiometabolic diseases, and cardiovascular diseases; pharmaceutical products development in the fields of oncology, immunology, cardiometabolic diseases, and cardiovascular diseases; scientific research for medical purposes in the fields of oncology, immunology, cardiometabolic diseases, and cardiovascular diseases; pharmaceutical research and development services in the fields of oncology, immunology, cardiometabolic diseases, and cardiovascular diseases; research and development of therapeutics for use in oncology, immunology, cardiometabolic diseases, and cardiovascular diseases; drug discovery services in the fields of oncology, immunology, cardiometabolic diseases, and cardiovascular diseases; research and development in the field of precision medicine for use in oncology, immunology, cardiometabolic diseases, and cardiovascular diseases; medical and scientific research in the fields of oncology, immunology, cardiometabolic diseases, and cardiovascular diseases
Owner
- Sandpiper Therapeutics, Inc., San Francisco, CA, US
- Sandpiper Therapeutics, Inc., San Francisco, CA, US
Prosecution history
- 21 Oct 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 26 Aug 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 Aug 2025 — PUBLISHED FOR OPPOSITION
- 20 Aug 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 18 Jul 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 18 Jul 2025 — EXAMINER'S AMENDMENT ENTERED
- 18 Jul 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 18 Jul 2025 — EXAMINERS AMENDMENT E-MAILED
- 18 Jul 2025 — EXAMINERS AMENDMENT -WRITTEN
- 01 Jul 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 01 Jul 2025 — NON-FINAL ACTION E-MAILED
- 01 Jul 2025 — NON-FINAL ACTION WRITTEN
- 17 Jun 2025 — ASSIGNED TO EXAMINER
- 29 Apr 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 07 Jan 2025 — APPLICATION FILING RECEIPT MAILED